- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00067782
A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy
April 7, 2011 updated by: Bristol-Myers Squibb
The purpose of this clinical research study is to learn if atazanavir is associated with serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for their previously administered protease inhibitor.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States
- Local Institution
-
-
California
-
West Hollywood, California, United States
- Local Institution
-
-
District of Columbia
-
Washington, District of Columbia, United States
- Local Institution
-
-
Florida
-
Altamonte Springs, Florida, United States
- Local Institution
-
Ft. Lauderdale, Florida, United States
- Local Institution
-
Miami, Florida, United States
- Local Institution
-
Tampa, Florida, United States
- Local Institution
-
-
Massachusetts
-
Boston, Massachusetts, United States
- Local Institution
-
-
Minnesota
-
Minneapolis, Minnesota, United States
- Local Institution
-
-
Missouri
-
St. Louis, Missouri, United States
- Local Institution
-
-
New Jersey
-
East Orange, New Jersey, United States
- Local Institution
-
-
New York
-
New York, New York, United States
- Local Institution
-
-
North Carolina
-
Huntersville, North Carolina, United States
- Local Institution
-
-
Ohio
-
Cleveland, Ohio, United States
- Local Institution
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
- Local Institution
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- Local Institution
-
-
South Carolina
-
Columbia, South Carolina, United States
- Local Institution
-
-
Texas
-
Fort Worth, Texas, United States
- Local Institution
-
Houston, Texas, United States
- Local Institution
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Must be on current HIV treatment regimen at least 3 to 6 months prior to study (this must be one protease inhibitor, or ritonavir-boosted protease inhibitor, and two nucleoside reverse transcriptase inhibitors) must be subject's first PI ever received
- Plasma HIV-1 RNA level < 50 c/mL within 3 to 6 months prior to study start
- Fasting LDL cholesterol > 130 mg/dL
Key Exclusion Criteria:
- WOCBP who do not use effective barrier contraception for any reason
- Women who are pregnant or breast feeding
- A life expectancy < 12 months
- Presence of a newly diagnosed HIV-related OI or any medical condition requiring acute therapy at the time of enrollment
- Cushing's Syndrome
- Uncontrolled diabetes mellitus, history of diabetic ketoacidosis or hyperosmolar syndrome
- Untreated hypothyroidism or hyperthyroidism
- Nephrotic syndrome or significant proteinuria
- Obstructive liver disease
- Active alcohol or substance abuse
- Proven or suspected acute hepatitis in the 30 days prior to study entry
- Intractable diarrhea (greater than or equal to 6 loose stools/day for at least 7 consecutive days) within 30 days prior to study start
- History of acute or chronic pancreatitis
- Inability to swallow capsules
- Presence of cardiomyopathy
- Known history of prolonged QTc interval
Any of the following:
- clinical symptoms potentially related to heart block
- heart rate < 40 bpm
- any of the following EKG abnormalities:
i) pause length > 3 seconds ii) second or third degree AV heart block iii) QTc interval > 450 msec for males iv) QTc interval > 470 msec for females
- Fasting serum triglyceride level > 750 mg/dL
Any of the following lab values within 2 weeks of starting study drug:
- serum creatinine greater to or equal to 1.5 times the upper limit of normal
- total serum lipase greater than or equal to 1.4 times the upper limit of normal
- liver transaminases greater than or equal to 3 times the upper limit of normal
- total serum bilirubin greater than or equal to 1.5 times the upper limit of normal
- Hypersensitivity to any component of the formulation of study drug
- Use of any lipid-lowering agent within 4 weeks prior or during study
- Use of a PI-containing ARV regimen prior to entry which is comprised of more than one PI
- Inclusion of an NNRTI in the PI-containing regimen
- Prisoners or subjects involuntary incarcerated for treatment of psychiatric or physical illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 2
|
Capsules, Oral, 400mg, Once daily, 48 weeks.
Other Names:
|
Active Comparator: 1
|
Capsules, Oral, 400mg, Once daily, 48 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Time to virologic rebound for subjects with HIV RNA < 50 c/mL at baseline; Magnitude/ durability of increases from baseline in absolute CD4 (Time-Averaged Difference) through WK12; Mean % change from baseline in fasting LDL cholesterol at WK12.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2002
Primary Completion (Actual)
March 1, 2005
Study Completion (Actual)
March 1, 2005
Study Registration Dates
First Submitted
August 27, 2003
First Submitted That Met QC Criteria
August 27, 2003
First Posted (Estimate)
August 28, 2003
Study Record Updates
Last Update Posted (Estimate)
April 14, 2011
Last Update Submitted That Met QC Criteria
April 7, 2011
Last Verified
January 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Atazanavir Sulfate
Other Study ID Numbers
- AI424-067
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Atazanavir (immediate switch)
-
Bristol-Myers SquibbCompletedHIV InfectionsUnited States, Canada
-
Azienda Ospedaliera San Gerardo di MonzaGilead SciencesCompletedQuality of Life | HIV-1 Infection | Impaired Cognition | Poor Quality Sleep | Depression/AnxietyItaly
-
Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsRecruitingHIV Infections | AIDS | Virologic FailureSouth Africa, Uganda
-
University of LiegeFonds National de la Recherche ScientifiqueCompletedSchizophrenia | Bipolar Disorder | Major Depressive Disorder | Schizo Affective DisorderBelgium
-
Niklaus LabhardtUniversity Hospital, Basel, Switzerland; Swiss Tropical & Public Health Institute and other collaboratorsCompleted
-
Kansas City Heart Rhythm Research FoundationKansas City Heart Rhythm Institute, Overland Park, KSRecruitingAtrial FibrillationUnited States
-
Laval UniversityCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie...Recruiting
-
Laval UniversityInstitut universitaire de cardiologie et de pneumologie de Québec, University...Not yet recruitingObesity | Obesity, MorbidCanada
-
Värmland County Council, SwedenActive, not recruitingObesity | Metabolic Syndrome | Malnutrition | Surgery
-
Tel-Aviv Sourasky Medical CenterUnknownPreserve Crestal Bone Level and Gingival Margin Around Dental ImplantsIsrael